blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1624874

EP1624874 - 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  10.09.2010
Database last updated on 15.06.2024
Most recent event   Tooltip19.10.2012Lapse of the patent in a contracting state
New state(s): TR		published on 21.11.2012  [2012/47]
Applicant(s)For all designated states
Merck Sharp & Dohme Corp.
126 East Lincoln Avenue
Rahway, NJ 07065 / US
[2010/10]
Former [2009/45]For all designated states
Merck & Co., Inc.
126 East Lincoln Avenue
Rahway, New Jersey 07065-0907 / US
Former [2006/07]For all designated states
Merck & Co., Inc.
126 East Lincoln Avenue Rahway
New Jersey 07065-0907 / US
Inventor(s)01 / BIFTU, Tesfaye
126 East Lincoln Avenue
Rahway, NJ 07065-0907 / US
02 / FENG, Danqing, Dennis
126 East Lincoln Avenue
Rahway, NJ 07065-0907 / US
03 / LIANG, Gui-Bai
126 East Lincoln Avenue
Rahway, NJ 07065-0907 / US
04 / QIAN, Xiaoxia
126 East Lincoln Avenue
Rahway, NJ 07065-0907 / US
 [2006/07]
Representative(s)Man, Jocelyn, et al
Merck & Co., Inc.
European Patent Department
Merck Sharp & Dohme Limited
Hertford Road, Hoddesdon
Hertfordshire, EN11 9BU / GB
[N/P]
Former [2006/48]Man, Jocelyn, et al
Merck & Co., Inc. European Patent Department Merck Sharp & Dohme Limited, Hertford Road, Hoddesdon
Hertfordshire, EN11 9BU / GB
Former [2006/07]Man, Jocelyn, et al
Merck & Co.,Inc. European Patent Department Terlings Park Eastwick Road
Harlow, Essex CM20 2QR / GB
Application number, filing date04751840.210.05.2004
[2006/07]
WO2004US14642
Priority number, dateUS20030470564P14.05.2003         Original published format: US 470564 P
[2006/07]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2004103276
Date:02.12.2004
Language:EN
[2004/49]
Type: A2 Application without search report 
No.:EP1624874
Date:15.02.2006
Language:EN
The application published by WIPO in one of the EPO official languages on 02.12.2004 takes the place of the publication of the European patent application.
[2006/07]
Type: B1 Patent specification 
No.:EP1624874
Date:04.11.2009
Language:EN
[2009/45]
Search report(s)International search report - published on:US11.08.2005
(Supplementary) European search report - dispatched on:EP25.10.2006
ClassificationIPC:C07D487/04, A61K31/55, A61P3/10
[2006/47]
CPC:
C07D487/04 (EP,US); A61P1/04 (EP); A61P1/18 (EP);
A61P29/00 (EP); A61P3/00 (EP); A61P3/04 (EP);
A61P3/06 (EP); A61P3/10 (EP); A61P5/28 (EP);
A61P9/10 (EP) (-)
Former IPC [2006/07]A61K31/55, A61P3/10, C07D491/00
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2006/07]
Extension statesALNot yet paid
HRNot yet paid
LT13.02.2006
LV13.02.2006
MKNot yet paid
TitleGerman:3-AMINO-4-PHENYLBUTANSÄUREDERIVATE ALS DIPEPTIDYLPEPTIDASE-HEMMER ZUR BEHANDLUNG ODER VORBEUGUNG VON DIABETES[2006/07]
English:3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES[2006/07]
French:DERIVES D'ACIDE 3-AMINO-4-PHENYLBUTANOIQUE EN TANT QU'INHIBITEURS DE DIPEPTIDYL PEPTIDASE DANS LE CADRE DU TRAITEMENT OU DE LA PREVENTION DU DIABETE[2006/07]
Entry into regional phase14.12.2005National basic fee paid 
14.12.2005Search fee paid 
13.02.2006Designation fee(s) paid 
13.02.2006Examination fee paid 
Examination procedure09.11.2005Amendment by applicant (claims and/or description)
13.02.2006Examination requested  [2006/15]
19.10.2007Despatch of a communication from the examining division (Time limit: M04)
19.02.2008Reply to a communication from the examining division
24.04.2009Communication of intention to grant the patent
04.09.2009Fee for grant paid
04.09.2009Fee for publishing/printing paid
Opposition(s)05.08.2010No opposition filed within time limit [2010/41]
Fees paidRenewal fee
27.03.2006Renewal fee patent year 03
07.05.2007Renewal fee patent year 04
18.03.2008Renewal fee patent year 05
02.06.2009Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT04.11.2009
BE04.11.2009
CY04.11.2009
CZ04.11.2009
DK04.11.2009
EE04.11.2009
FI04.11.2009
IT04.11.2009
NL04.11.2009
PL04.11.2009
RO04.11.2009
SE04.11.2009
SI04.11.2009
SK04.11.2009
TR04.11.2009
BG04.02.2010
GR05.02.2010
ES15.02.2010
PT04.03.2010
HU05.05.2010
IE10.05.2010
LU10.05.2010
CH31.05.2010
LI31.05.2010
MC31.05.2010
[2012/47]
Former [2012/44]AT04.11.2009
BE04.11.2009
CY04.11.2009
CZ04.11.2009
DK04.11.2009
EE04.11.2009
FI04.11.2009
IT04.11.2009
NL04.11.2009
PL04.11.2009
RO04.11.2009
SE04.11.2009
SI04.11.2009
SK04.11.2009
BG04.02.2010
GR05.02.2010
ES15.02.2010
PT04.03.2010
HU05.05.2010
IE10.05.2010
LU10.05.2010
CH31.05.2010
LI31.05.2010
MC31.05.2010
Former [2012/43]AT04.11.2009
BE04.11.2009
CY04.11.2009
CZ04.11.2009
DK04.11.2009
EE04.11.2009
FI04.11.2009
IT04.11.2009
PL04.11.2009
RO04.11.2009
SE04.11.2009
SI04.11.2009
SK04.11.2009
BG04.02.2010
GR05.02.2010
ES15.02.2010
PT04.03.2010
HU05.05.2010
IE10.05.2010
LU10.05.2010
CH31.05.2010
LI31.05.2010
MC31.05.2010
Former [2012/42]AT04.11.2009
BE04.11.2009
CY04.11.2009
CZ04.11.2009
DK04.11.2009
EE04.11.2009
FI04.11.2009
IT04.11.2009
PL04.11.2009
RO04.11.2009
SE04.11.2009
SI04.11.2009
SK04.11.2009
BG04.02.2010
GR05.02.2010
ES15.02.2010
PT04.03.2010
HU05.05.2010
IE10.05.2010
CH31.05.2010
LI31.05.2010
MC31.05.2010
Former [2011/19]AT04.11.2009
BE04.11.2009
CY04.11.2009
CZ04.11.2009
DK04.11.2009
EE04.11.2009
FI04.11.2009
IT04.11.2009
PL04.11.2009
RO04.11.2009
SE04.11.2009
SI04.11.2009
SK04.11.2009
BG04.02.2010
GR05.02.2010
ES15.02.2010
PT04.03.2010
IE10.05.2010
CH31.05.2010
LI31.05.2010
MC31.05.2010
Former [2011/15]AT04.11.2009
BE04.11.2009
CY04.11.2009
CZ04.11.2009
DK04.11.2009
EE04.11.2009
FI04.11.2009
IT04.11.2009
PL04.11.2009
RO04.11.2009
SE04.11.2009
SI04.11.2009
SK04.11.2009
BG04.02.2010
GR05.02.2010
ES15.02.2010
PT04.03.2010
CH31.05.2010
LI31.05.2010
MC31.05.2010
Former [2011/11]AT04.11.2009
BE04.11.2009
CY04.11.2009
CZ04.11.2009
DK04.11.2009
EE04.11.2009
FI04.11.2009
PL04.11.2009
RO04.11.2009
SE04.11.2009
SI04.11.2009
SK04.11.2009
BG04.02.2010
GR05.02.2010
ES15.02.2010
PT04.03.2010
CH31.05.2010
LI31.05.2010
MC31.05.2010
Former [2011/03]AT04.11.2009
BE04.11.2009
CY04.11.2009
CZ04.11.2009
DK04.11.2009
EE04.11.2009
FI04.11.2009
PL04.11.2009
RO04.11.2009
SE04.11.2009
SI04.11.2009
SK04.11.2009
BG04.02.2010
GR05.02.2010
ES15.02.2010
PT04.03.2010
MC31.05.2010
Former [2010/50]AT04.11.2009
BE04.11.2009
CY04.11.2009
CZ04.11.2009
DK04.11.2009
EE04.11.2009
FI04.11.2009
PL04.11.2009
RO04.11.2009
SE04.11.2009
SI04.11.2009
SK04.11.2009
BG04.02.2010
GR05.02.2010
ES15.02.2010
PT04.03.2010
Former [2010/39]AT04.11.2009
BE04.11.2009
CY04.11.2009
CZ04.11.2009
DK04.11.2009
EE04.11.2009
FI04.11.2009
PL04.11.2009
RO04.11.2009
SE04.11.2009
SI04.11.2009
SK04.11.2009
BG04.02.2010
ES15.02.2010
PT04.03.2010
Former [2010/36]AT04.11.2009
BE04.11.2009
CY04.11.2009
CZ04.11.2009
DK04.11.2009
EE04.11.2009
FI04.11.2009
PL04.11.2009
RO04.11.2009
SE04.11.2009
SI04.11.2009
BG04.02.2010
ES15.02.2010
PT04.03.2010
Former [2010/35]AT04.11.2009
BE04.11.2009
CY04.11.2009
DK04.11.2009
EE04.11.2009
FI04.11.2009
PL04.11.2009
RO04.11.2009
SE04.11.2009
SI04.11.2009
BG04.02.2010
ES15.02.2010
PT04.03.2010
Former [2010/31]AT04.11.2009
BE04.11.2009
CY04.11.2009
FI04.11.2009
PL04.11.2009
SE04.11.2009
SI04.11.2009
ES15.02.2010
PT04.03.2010
Former [2010/30]AT04.11.2009
CY04.11.2009
FI04.11.2009
PL04.11.2009
SE04.11.2009
SI04.11.2009
ES15.02.2010
PT04.03.2010
Former [2010/25]CY04.11.2009
FI04.11.2009
PL04.11.2009
SE04.11.2009
SI04.11.2009
ES15.02.2010
PT04.03.2010
Former [2010/23]FI04.11.2009
PL04.11.2009
SE04.11.2009
SI04.11.2009
ES15.02.2010
PT04.03.2010
Former [2010/22]FI04.11.2009
SE04.11.2009
ES15.02.2010
PT04.03.2010
Former [2010/19]ES15.02.2010
Documents cited:Search[A]WO03004498  (MERCK & CO INC [US], et al) [A] 1,14* claims 1,20 *
International search[AP]WO03082817  (MERCK & CO INC [US], et al)
by applicantWO03004498
    - J. DRUCKER, EXP. OPIN. INVEST. DRUGS, (2003), vol. 12, no. 1, pages 87 - 100
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.